You are here

  • Home
  • Archive
  • Volume 9, Issue 8
  • Adjuvant nivolumab for stage III/IV melanoma: evaluation of safety outcomes and association with recurrence-free survival

Article metrics

Article menu
XML
Clinical/translational cancer immunotherapy
Original research
Adjuvant nivolumab for stage III/IV melanoma: evaluation of safety outcomes and association with recurrence-free survival

 

Online download statistics by month:

Online download statistics by month: August 2021 to September 2025

AbstractFullPdf
Aug 2021266266113
Sep 2021882883317
Oct 2021434434133
Nov 202134234387
Dec 202122022361
Jan 202222122277
Feb 202217218452
Mar 202221121257
Apr 202222723273
May 202223023760
Jun 202219420152
Jul 202218619555
Aug 202223223947
Sep 202222523262
Oct 202221221666
Nov 202215916166
Dec 202213513525
Jan 202316716832
Feb 202313113227
Mar 202311011136
Apr 2023929223
May 202315215234
Jun 2023808020
Jul 2023707027
Aug 2023606016
Sep 2023565614
Oct 2023545412
Nov 2023636318
Dec 202361617
Jan 2024596018
Feb 2024535320
Mar 2024757974
Apr 2024535322
May 2024373820
Jun 2024414022
Jul 2024636525
Aug 2024414121
Sep 2024535327
Oct 2024434420
Nov 2024495016
Dec 2024787916
Jan 2025555533
Feb 2025333410
Mar 2025616124
Apr 202513613649
May 2025575737
Jun 2025343516
Jul 2025110
Sep 2025110
Total666767492139